{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:23:25Z","timestamp":1789190605130,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation t(11;14), but questions remain open about its optimal use. We have contacted all Hungarian haematology centers for their experience treating t(11;14) myeloma patients with venetoclax. 58 patients were reported. 37 received venetoclax in the relapsed\/refractory setting with few or no other therapeutic options available. 21 patients started venetoclax as salvage after failing to achieve satisfactory response to first line therapy. In the relapsed\/refractory setting objective response rate (ORR) was 94%, median progression-free survival (PFS) 10.0\u00a0months and median overall survival (OS) 14.6\u00a0months. In reinduction patients, ORR was 100%, median PFS and OS were not reached. Importantly, we found no adverse effect of high risk features such as deletion 17p or renal failure, in fact renal failure ameliorated in 42% of the cases, including three patients who became dialysis independent. Our study also reports the highest number of plasma cell leukemia cases successfully treated with venetoclax published in literature, with refractory plasma cell leukemia patients achieving a median PFS of 10.0 and a median OS of 12.2\u00a0months.<\/jats:p>","DOI":"10.3389\/pore.2022.1610276","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T04:11:45Z","timestamp":1646021505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers"],"prefix":"10.3389","volume":"28","author":[{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"F\u00e1bi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apor","family":"Hardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Rajnics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Rejt\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Szendrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e1r\u00f3czy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1002\/cncr.30770","article-title":"Outcome of Autologous Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma","volume":"123","author":"Veltri","year":"2017","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1080\/10428194.2020.1788014","article-title":"Primary Refractory Multiple Myeloma: a Real-World Experience with 85 Cases","volume":"61","author":"Jurczyszyn","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1016\/s2352-3026(19)30167-x","article-title":"Response-adapted Intensification with Cyclophosphamide, Bortezomib, and Dexamethasone versus No Intensification in Patients with Newly Diagnosed Multiple Myeloma (Myeloma XI): a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the Treatment of Multiple Myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 Family Proteins: Changing Partners in the Dance towards Death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-Cell Malignancies and Overcoming Therapeutic Resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of Venetoclax as Targeted Therapy for Relapsed\/refractory T(11;14) Multiple Myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(19)31711-8","article-title":"Surrogate Endpoints in Randomised Controlled Trials: a Reality Check","volume":"394","author":"Kumar","year":"2019","journal-title":"The Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.clml.2019.09.046","article-title":"A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"19","author":"Kumar","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): a Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL \u20102 with Venetoclax and Dexamethasone in Patients with Relapsed\/refractory T(11;14) Multiple Myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/bjh.16454","article-title":"Real\u2010world Data on Safety and Efficacy of Venetoclax\u2010based Regimens in Relapsed\/refractory T(11;14) Multiple Myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/jco.21.00443","article-title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, with or without Bortezomib, in Patients with Relapsed or Refractory Multiple Myeloma with and without T(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"Jco"},{"key":"B15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A Phase II Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed\/refractory Multiple Myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly Changing Myeloma Epidemiology in the General Population: Increased Incidence, Older Patients, and Longer Survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13325","article-title":"Translocation (11;14) in Newly Diagnosed Multiple Myeloma, Time to Reclassify This Standard Risk Chromosomal Aberration?","volume":"103","author":"Gran","year":"2019","journal-title":"Eur J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural History of T(11;14) Multiple Myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase Fluorescence In Situ Hybridization in Untreated AL Amyloidosis Has an Independent Prognostic Impact by Abnormality Type and Treatment Category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic Aberrations and Survival in Plasma Cell Leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the Treatment of Translocation (11;14) AL Amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e19538","DOI":"10.1200\/jco.2019.37.15_suppl.e19538","article-title":"Venetoclax Induces Sustained Complete Responses in Refractory\/relapsed Patients with Cardiac AL Amyloidosis","volume":"37","author":"Le Bras","year":"2019","journal-title":"Jco"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/j.clml.2019.09.538","article-title":"Preliminary Evidence of Efficacy of Venetoclax in Relapsed and Refractory AL Amyloidosis","volume":"19","author":"Premkumar","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax Induced a Complete Response in a Patient with Immunoglobulin Light Chain Amyloidosis Plateaued on Cyclophosphamide, Bortezomib and Dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination Therapy Incorporating Bcl-2 Inhibition with Venetoclax for the Treatment of Refractory Primary Plasma Cell Leukemia with T (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1002\/ajh.25331","article-title":"Single-agent Venetoclax Induces MRD-Negative Response in Relapsed Primary Plasma Cell Leukemia with T(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1002\/ajh.25676","article-title":"The Combination of Venetoclax, Daratumumab and Dexamethasone for the Treatment of Refractory Primary Plasma Cell Leukemia","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1111\/bjh.16858","article-title":"Secondary Plasma Cell Leukaemia Treated with Single Agent Venetoclax","volume":"190","author":"Glavey","year":"2020","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1177\/1078155219895072","article-title":"A Successful Case of Venetoclax-Based Therapy in Relapsed\/refractory Secondary Plasma Cell Leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4274\/tjh.galenos.2019.2019.0254","article-title":"Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study","volume":"37","author":"Wang","year":"2020","journal-title":"Turk J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1016\/j.clml.2019.07.316","article-title":"Unexpected Equal Long-Term Overall Survival of Multiple Myeloma Harboring T(11;14), or T(4;14): A Retrospective Single Center Study","volume":"19","author":"Hardi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: a Multicenter IMWG Study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/Amplification of Chromosome Arm 1q21 in Multiple Myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q Is Associated with Early Progression in Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 Gains Confer Inferior Outcomes in Multiple Myeloma Treated with Bortezomib but Copy Number Variation and Percentage of Plasma Cells Involved Have No Additional Prognostic Value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Despite Novel Agent-Based Induction Regimens and Autologous Transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple Myeloma with 1q21 Amplification Is Highly Sensitive to MCL-1 Targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"key":"B42","unstructured":"Potential Interactions for CLL\/SLL [Internet]2021"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax Plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy: a Phase 3 Randomized Placebo-Controlled Trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-134850","article-title":"CYP3A Inhibitors and Impact of These Agents on Outcomes in Patients with Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine on the VIALE-A Study","volume":"136","author":"Jonas","year":"2020","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-hodgkin Lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B46","first-page":"A11835","article-title":"Abstract 11835: Evaluation of Cardiovascular Adverse Events Associated with Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia","volume":"138","author":"Hetavi","year":"2018","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1556\/oh.2012.29270","article-title":"Study of Incidence and Treatment of Acute Myocardial Infarction by Evaluating the Financing Database: 2004-2009","volume":"153","author":"Belicza","year":"2012","journal-title":"Orvosi Hetilap"},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High Incidence of Arterial Thrombosis in Young Patients Treated for Multiple Myeloma: Results of a Prospective Cohort Study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of Cardiovascular Risk in Patients with Multiple Myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/nejmoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.3324\/haematol.2019.228338","article-title":"Successful Venetoclax Salvage in the Setting of Refractory, Dialysis-dependent Multiple Myeloma with T(11;14)","volume":"105","author":"Swan","year":"2020","journal-title":"Haematologica"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T04:11:49Z","timestamp":1646021509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":51,"alternative-id":["10.3389\/pore.2022.1610276"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610276","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"1610276"}}